A U.S. appeals court has affirmed a lower court order blocking Novartis (NVS+0.4%) unit Sandoz from selling a generic version of Allergan’s (AGN+0.4%) eye drop Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension, while the patent infringement suit is pending.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.